Brigham and Women’s Hospital cardiovascular experts will present their latest research at this year’s American College of Cardiology 2024 Scientific Session & Expo, held April 6–8 in Atlanta, GA.

Paul M. Ridker, MD, MPH, of the Center for Cardiovascular Disease Prevention at Brigham and Women’s Hospital, and colleagues found inflammation assessed by hsCRP predicted cardiovascular events and death at least as strongly as LDLC when comparing bempedoic acid with placebo in statin-intolerant patients.

Shinichi Goto, PhD, at Brigham and Women’s Hospital, and colleagues have developed a deep learning–based model that detects subtle changes in standard 12-lead electrocardiography data to flag patients who should undergo echocardiography to evaluate possible atrial septal defect.

The fact that cardiovascular disease is the leading cause of death in women is wildly underappreciated, says the Brigham’s JoAnn E. Manson, MD, MPH, DrPH. Dr. Manson has led many seminal research projects focused on women’s health and set the foundation for related advances at the Brigham today.

Brigham and Women’s Hospital researchers conducted a patient-level meta-analysis of ACUITY plus four other large randomized trials. Bivalirudin was not associated with any significant difference in 30-day effectiveness outcomes compared with heparin, but had a substantially better safety profile.